Mebendazole for Glioblastoma: Phase I Data and BBB Penetration
Mebendazole has Phase I clinical trial data in glioblastoma, confirmed blood-brain barrier penetration, and costs $5/month. The strongest repurposed drug candidate for brain tumors.
🔬 Grade B: PromisingThe Bottom Line
Mebendazole has the strongest case among repurposed drugs for glioblastoma (GBM). A Phase I clinical trial (NCT01729260) at Johns Hopkins enrolled 24 patients with high-grade gliomas and confirmed safety at cancer-relevant doses. Mebendazole crosses the blood-brain barrier, a critical advantage that most drugs lack. The preclinical data in GBM models is extensive, and the ReDO Project ranked it as a top candidate for brain tumors.
Why Glioblastoma Needs Repurposed Drugs
GBM is the deadliest brain tumor: median survival is 15-18 months with standard treatment (surgery + radiation + temozolomide). The blood-brain barrier (BBB) blocks most drugs from reaching the brain, making GBM one of the hardest cancers to treat. Any drug that crosses the BBB and has anticancer activity is immediately relevant.
The Johns Hopkins Phase I Trial (NCT01729260)
- Patients: 24 total (18 glioblastoma, 6 anaplastic gliomas)
- Treatment: Mebendazole 500mg TID, escalating, combined with temozolomide
- Key findings: Mebendazole was safe and well-tolerated at high doses. BBB penetration confirmed.
- Significance: This is the essential first step. Safety data enables larger efficacy trials.
Why Mebendazole for Brain Tumors
- BBB penetration: Confirmed in human studies. This alone eliminates most repurposed drug candidates.
- Tubulin disruption: Same mechanism as vincristine, which is used in brain tumor protocols but has dose-limiting neurotoxicity. Mebendazole is far better tolerated.
- Hedgehog pathway: Aberrantly activated in GBM stem cells. Mebendazole inhibits Hedgehog signaling.
- Synergy with temozolomide: Preclinical data shows enhanced effects when combined with the standard GBM chemotherapy.
- Cancer stem cells: GBM recurrence is driven by cancer stem cells that resist radiation and chemo. Mebendazole targets these cells through multiple mechanisms.
Preclinical GBM Data
- PMC9862092 (2023): Comprehensive review of mebendazole as a repurposed drug specifically for brain cancers. Concluded it is an "ideal candidate."
- In vivo mouse GBM models showed significant tumor growth inhibition with oral mebendazole
- Combination with disulfiram + copper (also BBB-penetrant) showed synergistic effects in preclinical GBM models
Practical Information
- Dose (from trials): 500mg twice daily with fatty food
- Must take with fat: Absorption drops dramatically without dietary fat
- Monitoring: Liver function tests periodically (hepatotoxicity possible at high doses)
- Prescription: Any physician can prescribe mebendazole off-label. Show them the NCT01729260 data and the PMC9862092 review.
- Cost: $5-15/month generic
- Not fenbendazole: The veterinary drug fenbendazole does NOT have confirmed BBB penetration in humans. Mebendazole does.
Other Repurposed Drugs for GBM
- Disulfiram + Copper: JAMA RCT in recurrent GBM. Crosses BBB. Targets cancer stem cells via cuproptosis.
- DCA: Michelakis Phase I in GBM. Reverses Warburg effect in brain tumor tissue.
- Ivermectin: Multi-target mechanism but BBB penetration at therapeutic levels uncertain in humans.
Sources
- ClinicalTrials.gov NCT01729260: Phase I mebendazole in high-grade gliomas
- PMC9862092 (2023): "Emerging Perspectives on Mebendazole as a Repurposed Drug for Brain Cancers" pmc.ncbi.nlm.nih.gov
- ecancer.org: ReDO Project mebendazole review ecancer.org
Medical Disclaimer: This is a research review, not medical advice. Always consult with qualified healthcare professionals before making any changes to your health regimen.
How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →